1. Introduction {#sec1}
===============

Spinal muscular atrophies (*SMA*s) are a group of motor neuron disorders characterized by degeneration of spinal cord anterior horn cells, leading to muscular wasting and atrophy \[[@B1]\]. *SMA* is the most common autosomal recessive disorder after cystic fibrosis, with an estimated 1/10,000 incidence and a 1/60 carrier frequency \[[@B2]\]. Affected patients are classified into four groups according to age at onset and phenotype severity \[[@B3], [@B4]\]. Type I *SMA* or the Werdnig-Hoffmann disease (OMIM No. 253300) is the most severe form, with an onset within the first 6 months of age, severe generalized muscle weakness with hypotonia, and death before two years of age. In type II *SMA* (OMIM No. 253550), affected children sit unassisted, may be able to walk for a short distance, and usually survive over 10 years of age. Type III *SMA* or the Kugelberg-Welander disease (OMIM No. 253400) has its onset in the first to third decade. Though its course is highly variable, patients are constantly able to walk unassisted. Type IV *SMA* or adult-onset *SMA* (OMIM No. 271150) is quite rare.

The survival motor neuron (*SMN*) gene, implicated in the four forms of *SMA*, maps to chromosome 5q 11.2--13.3 \[[@B5]--[@B7]\] and is duplicated as telomeric and centromeric copies, so called *SMN*1 (OMIM No. 600354) and *SMN*2 (OMIM No. 601627), respectively \[[@B8], [@B9]\]. *SMN*1 and *SMN*2 comprising 8 exons are highly homologous, with only five base-pair differences within their 3′ ends \[[@B8], [@B10]\], and thus encode nearly identical proteins. Two of these base-pairs, located in exons 7 and 8, allow *SMN*1 to be distinguished from *SMN*2 at DNA and RNA levels and are currently used for detection of *SMN*1 deletions \[[@B11]\]. A vast majority (90--98%) of *SMA* patients have homozygous deletions of *SMN*1 exons 7 and 8 \[[@B8], [@B12], [@B13]\], the remaining ones carrying *SMN*1 intragenic mutations \[[@B8], [@B14], [@B15]\], with a frequency higher in type I than in types II and III.

Conversely, *SMN*2 homozygous inactivation is not directly responsible for *SMA* \[[@B8]\]. A number of studies have however shown that *SMN*2 acts as a modulator of *SMA* severity, with an inverse correlation between the *SMN*2 copy number and the disease severity \[[@B16], [@B17]\]. Failure of *SMN*2 to fully compensate homozygous loss of *SMN*1 is due to a sequence difference in exon 7 which causes alternative splicing of the *SMN*2 gene, and subsequently lower amount of full-length protein \[[@B8], [@B18], [@B19]\].

The neuronal apoptosis inhibitory protein gene (*NAIP*) \[[@B20]\], close to the *SMN* genes (15, 5 kb) at 5q11--q13, was initially considered as a candidate gene for *SMA* \[[@B12], [@B20], [@B21]\]. While subsequent studies have ruled out its direct responsibility, for this disease \[[@B17], [@B22]\], *NAIP* has however shown to be more frequently mutated in *SMA* affected patients than in general population, with homozygous deletions in 45--67% of typeI and 20--42% of typeII/typeIII *SMA* patients \[[@B12], [@B20], [@B23]--[@B25]\].

Analysis of deletions encompassing both *NAIP* and *SMN* genes in a large number of *SMA* patients suggests that loss of *NAIP* may be associated with a higher disease severity \[[@B10], [@B20]\]. Here we investigated the clinical and molecular characteristics of 92 Algerian *SMA* patients from 57 families to assess the prevalence of *SMN*1 deletions and the combined impact of *SMN*2 copy number and *NAIP* deletions on clinical severity.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

92 patients from 57 Algerian families were diagnosed as having SMA on the basis of clinical findings and electromyoneurography. All patients fulfilled the diagnostic criteria for proximal SMA, as defined by the International SMA Collaboration \[[@B27]\] and by Zerres et al. \[[@B26]\] ([Table 1](#tab1){ref-type="table"}). Inclusion and exclusion criteria were similar to those proposed by the International SMA Collaboration \[[@B27]\]. Patients with symmetrical, muscle weakness of trunk and limbs, proximal muscles weakness more than distal, lower limbs involvement more than upper limbs, and fasciculations of tongue and tremor of hands and in whom denervation was seen on EMG were included in our study. Patients who presented with CNS dysfunction, sensory loss, eye or facial muscle weakness, or involvement of other organs were excluded from this study. A complete clinical history was recorded with emphasis on age, sex, age at onset, course of the disease, perinatal history, parental consanguinity, and affected relatives. Clinical examination focused on neurological parameters, tone, power, reflexes, wasting and atrophy of muscles, and abnormal movements and sensations. Other investigations included serum creatine phosphokinase (CPK), electromyogram (EMG), and nerve conduction velocity.

2.2. Methods {#sec2.2}
------------

After informed consent, DNA was extracted from peripheral blood samples according to a standard technique \[[@B28]\].

### 2.2.1. Molecular Analysis of *SMN* Genes {#sec2.2.1}

Search for *SMN*1 exons 7 and 8 deletions was performed by PCR and restriction enzyme digestion, as described in \[[@B29]\]. The *SMN*2 copy number was determined by Multiplex Ligation-dependent Probe Assay \[[@B30], [@B31]\].

### 2.2.2. Molecular Analysis of the *NAIP* Gene {#sec2.2.2}

All individuals were also tested for exons 4 and 5 deletion of the *NAIP*gene. PCR conditions and primers used to amplify exons 4 and 5 were identical to those of Roy et al. \[[@B20]\].

3. Results {#sec3}
==========

3.1. Clinical and Genealogical Findings {#sec3.1}
---------------------------------------

The rate of consanguineous marriage in this study was approximately 47%. Degrees of consanguinity are listed in [Table 2](#tab2){ref-type="table"}.

Twenty-two of the 57 families (39%) were multiplex. The most common type in our cohort was type III, with fifty-three (53) affected cases from 31 families (60%), followed by type I with 20 cases from 14 families (25%). Frequency of the different types is summarized in [Table 3](#tab3){ref-type="table"}.

In the *SMA* type I group, the age at onset varied from birth to 6 months, with an average of 5 ± 2, 5 months. All patients were mentally alert. The main symptom was severe hypotonia with poor limb mobility. Only two patients could hold up their heads, for a short period of time. Twelve patients (60%) died between 2 and 53 months of age, due to respiratory failure following respiratory tract infections. The remaining ones are still alive (the oldest patient is currently 72 months old). All patients with prolonged survival suffered from joint contractures caused by progressive muscular atrophy, spine deformation as scoliosis or kyphoscoliosis, and swallowing difficulties. The Bulbar symptoms were observed in 5 patients of them ([Table 4](#tab4){ref-type="table"}). They were not able to cope with everyday routine and thus were totally family dependent. The DNA analysis showed that the *SMN*1 gene is interrupted in five out of six *SMA* type I patients with prolonged survival, and only one patient showed homozygous deletion of *NAIP* gene ([Table 4](#tab4){ref-type="table"}). The *SMN*2 copy number was determined in 5 *SMA* type I patients carrying homozygous *SMN*1 deletions, and two of them (2/5) had two *SMN*2 copies, the remaining ones (3/6) carrying 3 *SMN*2 copies ([Table 4](#tab4){ref-type="table"}).

In the *SMA* type II group, age of onset ranged from 8 to 18 months (average 12, 7 ± 3, and 3 months). They were defined by ability to sit alone. Some children experienced early difficulty for sitting or rolling over (2 patients), while 3 patients were able to crawl and stand with support at a mean age of 22 months for a period of 4 months, and two patients were able to walk with support for a period of 6 months. None walked unaided. Scoliosis and contractures constantly developed in the patients who all became wheelchair dependent (6/16). In the type II group all patients are still alive, and 4/16 patients (25%) survive beyond age 15. In the *SMA* type III group, clinical onset ranged from the first year of life to the 3rd decade. Twenty-two patients (41, 5%) were confined to a wheelchair at ages ranging from 10 to 34 years, the remaining ones being still able to walk, with support. Hand tremor was found in 26 out of the 53 patients type III. Distal muscle weakness and/or amyotrophy was associated with the classical proximal defect, with frequent spine deformities and contractures in 39 patients. Life span was not significantly reduced.

*SMA* type II and III patients coexisted within 2 families. In the three adult-onset *SMA* patients (type IV), age of onset ranged from 20 to 41 years (mean age of onset 30 ± 8 years). Adult *SMA* patients, except for patient 2, had very mild phenotypes, compared with the childhood onset.

Blood CPK activity was normal in all *SMA* type I patients and was occasionally normal or slightly elevated in patients with type II (3 patients) or type III *SMA* (14 patients). In EMG examination the increased mean potentials, amplitude, duration, and area were stated. Maximal effort pattern in both proximal and distal muscles was reduced; spontaneous activity fibrillation and occasional fasciculations were present. Motor conduction velocity and sensory nerve conduction were normal.

3.2. Molecular Findings {#sec3.2}
-----------------------

Homozygous deletions of *SMN*1 exon 7, exon 8, or both were observed in 43/57 families (75%) with the following distribution: type I 11/14, type II 7/10, type III 24/31, and type IV 1/2. Among the 43 families with deletions, 36 had both exons 7 and 8 deleted, while four had deletions only of exon 7, and 3 patients carried only homozygous deletion restricted to *SMN*1 exon 8 ([Table 5](#tab5){ref-type="table"}). Homozygous deletions of exons 4 and/or 5 of the *NAIP* gene were found in 4/14 type I, 2/10 type II, 9/31 type III, and 0/2 type IV families ([Table 5](#tab5){ref-type="table"}). Homozygous *NAIP* deletions were constantly associated with homozygous *SMN*1 deletions.

The *SMN*2 copy number was determined in patients carrying homozygous *SMN*1 deletions *n* = 62 ([Table 6](#tab6){ref-type="table"}). 11/15 (73%) *SMA* type I patients had one or two *SMN*2 copies, the remaining ones carrying 3 *SMN*2 copies, 10/12 (83%) type II patients carried three or four *SMN*2 copies, the remaining ones having 2 *SMN*2 copies, and 32/33 (96%) type III patients carried three or four *SMN*2 copies. Finally, both adult onset patients carried at least 5 *SMN*2 copies ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

We analyzed three genes implicated in *SMA*, namely, *SMN*1, *SMN*2, and *NAIP*, in a cohort of 92 *SMA* affected patients from 57 Algerian families, in an attempt at phenotype/genotype correlation. All patients fulfilled the diagnostic criteria for proximal *SMA*, as defined by the International *SMA* Collaboration \[[@B26]\] and were classified into four subgroups according to the criteria of Zerres et al. \[[@B27]\]. Twenty patients had type I, 16 patients type II, 53 type III, and 3 patients type IV *SMA*. Though clinical classification of *SMA* is helpful in providing medical care and prognostic assessment; it is however based on subjective and arbitrary parameters which may still be controversial and subject to errors. Zerres and Rudnik-Schöneborn \[[@B32]\], in a retrospective study of 445 *SMA* patients, found 106 cases (24%) that could not be classified and suggested subdividing type III *SMA* into two groups, resulting in a total of four *SMA* types. In the present study, clinical classification of patients into four groups, based on criteria of the International *SMA* collaboration \[[@B26]\] and of Zerres and Rudnik-Schöneborn \[[@B32]\], was possible for most patients. In these classifications, age at onset is classically considered to be predictive of the outcome. However, in 11 cases (12%) age at onset and/or death and motor milestones (ability to walk independently) did clearly overlap between two subsets. It is thus important to keep in mind the possibility of long-standing disease courses with an early onset of weakness compatible with a prolonged survival. For example, 6 patients with *SMA* type I survived over age two. In 5 patients, age at onset was before 18 months, which is characteristic of type II *SMA*, while walking capacities were compatible with *SMA* type III. Coexistence of various types of *SMA* (II and III) within a given family occurred in our series (2/57 families), as reported elsewhere \[[@B33], [@B34]\], in favor of a continuous spectrum in childhood *SMA*. Additionally we found a predominance of males to females (17 female/36 males) in type III *SMA*, as previously reported by Rudnik-Schöneborn et al. who suggested the presence of a female sparing factor \[[@B35]\]. Tazir and Geronimi reported the same fact in a much larger Algerian series in which chronic cases were predominant \[[@B36]\].

Consanguinity rate was 47% in our cohort, that is above the average reported in the Algerian general population (*≈*39%) \[[@B37]\]. Furthermore twenty-four families (42%) had a positive history of affected relatives. These data emphasize the importance of lowering the consanguinity rate and the value of genetic counseling and prenatal diagnosis for preventing *SMA* in our community.

From molecular point of view, the proportion of *SMN*1 homozygous deletions was 75% in our study. lower than those found in several other previously reported population studies \[[@B38]--[@B42]\] ([Table 7](#tab7){ref-type="table"}).

Deletions involving both exons 7 and 8 were observed in 36 families (63%), being much more frequent than deletions restricted to exon 7 (4 families, 7%) or 8 (3 families, 5%), in agreement with previous investigations \[[@B8], [@B23], [@B42], [@B43]\].

Several authors reported a frequency of large deletions, encompassing both *SMN* and *NAIP* genes, higher in *SMA* type I than in the other types \[[@B12], [@B25], [@B43]--[@B56]\].

In our study the frequency of *NAIP* gene deletions was 28%, 20%, and 16% for type I, II, and III, respectively, and did apparently not influence the disease severity.

Moreover, a great proportion of severely affected patients harboured no *NAIP* deletion, and the same pattern of deletions (involving *SMN* and *NAIP* genes) was found among affected sibs with different phenotypes (*SMA* II and *SMA* III). This supports the hypothesis that other factors may regulate the severity of the clinical course in addition to the extent of the deletion \[[@B17], [@B57]\]. The *SMN*2 gene was consistently present as at least one copy in our series, thus contributing to some amount of *SMN* protein \[[@B56], [@B59]\]. It has previously been reported that most *SMN*2 transcripts lack exon 7 and are thus functionally defective, reinforcing the view that the disease is the result of an insufficient amount of intact *SMN* protein \[[@B60]\]. Interestingly, no patient has been diagnosed with a homozygous absence of both *SMN*1 and *SMN*2 gene so far, suggesting that a total absence of *SMN* would be lethal in utero.

The results of our quantitative analysis of *SMN*2 gene copies clearly show that the disease phenotype is influenced by the number of copies of the *SMN*2 gene, consistent with previous studies indicating that type II and III patients have on average a larger number of *SMN*2 copies than type I *SMA* patients \[[@B61]--[@B64a]\]. In our series of 11 *SMA* type I patients who had a determination of the *SMN*2 copy number, the two patients with one *SMN*2 copy had a median survival of 5 months, whereas those with two and three *SMN*2 copies survived 8 and 23 months, respectively.

It is classically admitted that the *SMN*2 copy number is less than 3 in *SMA* type I and at least 3 in *SMA* type II, III, and IV \[[@B63]--[@B65]\]. Such a correlation between the number of *SMN*2 genes and the clinical phenotype is however not conclusive.

In conclusion, our results are in agreement with the general consensus that there is no correlation between the size of *SMN*1 deletions and the clinical severity of *SMA* and that there exists a close relationship between *SMN*2 copy number and *SMA* disease severity, suggesting that the determination of *SMN*2 copy number may be a good predictor of *SMA* disease type. We suggest that other still unknown factors may regulate the severity of the clinical course and influence phenotype expression. Our study additionally understanding the function of the *SMN* protein would probably be the key in unraveling the molecular basis of *SMA*.
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Electronic Database Information
===============================

Accession numbers and the URL for data presented herein are as follows: Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for type I *SMA* \[MIM 253300\], type II *SMA* \[MIM 253550\], type III *SMA* \[MIM 253400\], *SMN1*\[MIM 600354\], and *SMN2*\[MIM 601627\]).

###### 

Classification of autosomal recessive proximal spinal atrophy as defined by Zerres et al. \[[@B27]\].

  Type   Definition
  ------ -----------------------------
  I      Never able to sit
  II     Able to sit but not to walk
         Able to walk
  III    \(a\) Onset before 3 years
         \(b\) Onset 3--30 years
  IV     Onset after 30 years

###### 

Consanguinity in Algerian *SMA* Families.

  Degree of inbreeding   No. of families
  ---------------------- -----------------
  2nd degree             7 (12,28%)
  3rd degree             10 (17,54%)
  4th degree             8 (14%)
  Distant relatives      3 (5%)
  Unrelated              29 (51%)

###### 

Frequency of *SMA* types.

  *SMA* type   No. of cases   No. of families
  ------------ -------------- -----------------
  I            20             14
  II           16             10
  III          53             31
  IV           3              2
                              
  Total        92             57

###### 

Phenotypic and genotypic analysis of the 6 *SMA* type I index patients with prolonged survival.

  Phenotypic and genotypic analysis   N° 1   N° 2   N° 3   N° 4   N° 5   N° 6
  ----------------------------------- ------ ------ ------ ------ ------ -------
  Sex                                 F      M      M      M      M      M
  Consanguinity                       −      −      −      \+     −      \+
  Age at onset (months)               4      2      4      6      4      Birth
  Age at diagnosis (year)             4      5      5      3      2      2
  Age at last information (months)    50     60     72     39     48     41
  Lifting of head                     \+     \+     \+     \+     −      −
  Hypotonia and muscle weakness       \+     \+     \+     \+     \+     \+
  Deep tendon reflexes                −      −      −      −      −      −
  Fasciculations                      −      −      \+     −      \+     −
  Bulbar symptoms                     \+     \+     \+     \+     \+     −
  Breathing difficulties              \+     −      −      −      −      −
  Frequent pneumonia                  \+     \+     \+     \+     \+     \+
  Age at death (months)               54     −      −      −      −      −
  *SMN*1 gene deletion                Yes    Yes    Yes    No     Yes    Yes
  *NAIP* gene deletion                Yes    No     No     No     No     No
  *SMN*2 copy number                  2      2      3      −      3      3

###### 

Distribution of homozygous deletion of *SMN*1 and *NAIP* genes according to the different types of *SMA*.

  *N* of families        *SMN*1 gene deletion   *NAIP* gene deletion              
  ---------------------- ---------------------- ---------------------- ---------- ---------
  *SMA* I (*n* = 14)     2 (14%)                1 (7%)                 8 (57%)    4 (28%)
  *SMA* II (*n* = 10)    1 (10%)                0                      6 (60%)    2 (20%)
  *SMA* III (*n* = 31)   1 (3%)                 2 (6%)                 21 (67%)   9 (29%)
  *SMA* IV (*n* = 2)     0                      0                      1 (50%)    0

###### 

Analysis of the *SMN*2 copy number in the 62 patients with homozygous absence of the *SMN*1 gene.

  *SMA* type   *N* patients   *SMN*2 copy number                                  
  ------------ -------------- -------------------- --------- --------- ---------- ----------
  I            15             2 (13%)              9 (60%)   4 (26%)   0          0
  II           12             0                    2 (16%)   7 (58%)   3 (25%)    0
  III          33             0                    0         5 (15%)   27 (81%)   1 (3%)
  IV           2              0                    0         0         0          2 (100%)

###### 

Frequency of *SMN*1 homozygous deletion in *SMA* around the world.

  References    Countries           *N* patients   *SMN*Del (%)
  ------------- ------------------- -------------- --------------
  \[[@B38]\]    Korea 2001          37             32,43%
  \[[@B39]\]    Vietnam 2003        17             41,17%
  \[[@B40]\]    Johannesburg 2007   92             51%
  \[[@B41]\]    Egypt 2001          33             55%
  \[[@B42]\]    Russia 2001         57             65%
  \[[@B33]\]    Brasilia 1999       87             69%
  *Our study*   *Algeria 2009*      *92*           *75%*
  \[[@B43]\]    India 2005          45             76%
  \[[@B44]\]    Saudi Arabia 1997   16             82%
  \[[@B45]\]    Morocco 2003        54             83,33%
  \[[@B46]\]    Turkey 2000         60             85%
  \[[@B47]\]    Germany 1995        195            90%
  \[[@B48]\]    Spain 1995          54             91%
  \[[@B49]\]    Holland 1995        103            93%
  \[[@B50]\]    Japan 2002          32             94%
  \[[@B51]\]    Tunis 2006          60             95%
  \[[@B52]\]    Iran 2004           22             95,40%
  \[[@B24]\]    UK 1995             140            97,80%
  \[[@B53]\]    Kuwait 2001         46             97,82%
  \[[@B8]\]     France 1995         229            98%
  \[[@B54]\]    Taiwan 1995         42             100%
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